Loading clinical trials...
Loading clinical trials...
The study is expected to identify a safe dose of BMS-754807 to be given in combination with a standard dose of cetuximab and the recommended dose or dose range for Phase II studies. The study is also ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more
NCT07066046 · Colorectal Cancer (CRC), Adenomatous Polyposis, and more
NCT07162337 · Colorectal Cancer Prevention, Colorectal Adenoma
NCT05780684 · Colorectal Cancer, Esophagus Cancer, and more
NCT06287723 · Colorectal Cancer, Liver Metastases, and more
Nebraska Methodist Hospital
Omaha, Nebraska
Duke University Medical Center
Durham, North Carolina
University Of Wisconsin
Madison, Wisconsin
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions